These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 2454471)

  • 1. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
    Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
    Nara PL; Robey WG; Arthur LO; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC; Fischinger PJ
    J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Palker TJ; Clark ME; Langlois AJ; Matthews TJ; Weinhold KJ; Randall RR; Bolognesi DP; Haynes BF
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1932-6. PubMed ID: 2450351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunodominant B-cell clones responsive to an HIV-1 neutralization and cell fusion inhibition epitope in chimpanzee-to-chimpanzee passages of HTLV-IIIB and LAV-1.
    Goudsmit J; Bakker M; Smit L
    Res Virol; 1989; 140(5):405-18. PubMed ID: 2479965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity.
    Meloen RH; Liskamp RM; Goudsmit J
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1505-12. PubMed ID: 2471813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody recognition of amino acid divergence within an HIV-1 neutralization epitope.
    Goudsmit J; Zwart G; Bakker M; Smit L; Back N; Epstein L; Kuiken C; d'Amaro J; de Wolf F
    Res Virol; 1989; 140(5):419-36. PubMed ID: 2479966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.
    Arthur LO; Bess JW; Waters DJ; Pyle SW; Kelliher JC; Nara PL; Krohn K; Robey WG; Langlois AJ; Gallo RC
    J Virol; 1989 Dec; 63(12):5046-53. PubMed ID: 2555541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
    Matsushita S; Robert-Guroff M; Rusche J; Koito A; Hattori T; Hoshino H; Javaherian K; Takatsuki K; Putney S
    J Virol; 1988 Jun; 62(6):2107-14. PubMed ID: 2452899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein.
    Matthews TJ; Langlois AJ; Robey WG; Chang NT; Gallo RC; Fischinger PJ; Bolognesi DP
    Haematol Blood Transfus; 1987; 31():414-22. PubMed ID: 2832276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF.
    Pyle SW; Dubois GC; Robey WG; Bess JW; Fischinger PJ; Arthur LO
    J Virol; 1988 Jul; 62(7):2258-64. PubMed ID: 3163739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
    Palker TJ; Matthews TJ; Langlois A; Tanner ME; Martin ME; Scearce RM; Kim JE; Berzofsky JA; Bolognesi DP; Haynes BF
    J Immunol; 1989 May; 142(10):3612-9. PubMed ID: 2469721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable and conserved neutralization antigens of human immunodeficiency virus.
    Weiss RA; Clapham PR; Weber JN; Dalgleish AG; Lasky LA; Berman PW
    Nature; 1986 Dec 11-17; 324(6097):572-5. PubMed ID: 2431324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.
    Nara PL; Robey WG; Pyle SW; Hatch WC; Dunlop NM; Bess JW; Kelliher JC; Arthur LO; Fischinger PJ
    J Virol; 1988 Aug; 62(8):2622-8. PubMed ID: 3392769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine.
    Arthur LO; Pyle SW; Nara PL; Bess JW; Gonda MA; Kelliher JC; Gilden RV; Robey WG; Bolognesi DP; Gallo RC
    Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8583-7. PubMed ID: 3479807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity of chimpanzee antibodies binding a strain-specific HIV-1 neutralization epitope of the external envelope.
    Goudsmit J; Bakker M; Smit L; Meloen RH
    J Med Primatol; 1989; 18(3-4):357-62. PubMed ID: 2474656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.
    Matthews TJ; Langlois AJ; Robey WG; Chang NT; Gallo RC; Fischinger PJ; Bolognesi DP
    Proc Natl Acad Sci U S A; 1986 Dec; 83(24):9709-13. PubMed ID: 2432599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
    Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J
    Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
    Nara PL; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Gallo RC; Fischinger PJ; Goudsmit J
    J Virol; 1990 Aug; 64(8):3779-91. PubMed ID: 2370681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120.
    Nara PL; Robey WG; Gonda MA; Carter SG; Fischinger PJ
    Proc Natl Acad Sci U S A; 1987 Jun; 84(11):3797-801. PubMed ID: 3473484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees.
    Goudsmit J; Thiriart C; Smit L; Bruck C; Gibbs CJ
    Vaccine; 1988 Jun; 6(3):229-32. PubMed ID: 3166553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.